These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26077306)

  • 1. [Anamnesis, Pathological Assessment, Therapeutic Features and Course of Disease: Retrospective Study on Clinical-Based Factors for Prediction of Cancer-Specific Survival of 378 Patients with Stage pT1 Urothelial Bladder Carcinoma].
    Breyer J; Otto W; Hartmann A; Bumes B; Bründl J; Gierth M; Bertz S; Denzinger S; Burger M; Lausenmeyer EM
    Aktuelle Urol; 2015 May; 46(3):221-6. PubMed ID: 26077306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
    Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
    BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory).
    Sözen S; Akbal C; Sökmensüer C; Ekici S; Ozen H
    Urol Int; 2002; 69(3):200-6. PubMed ID: 12372888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic impact of blood transfusion on cancer-specific survival after radical cystectomy irrespective of tumor stage.
    Buchner A; Grimm T; Schneevoigt BS; Wittmann G; Kretschmer A; Jokisch F; Grabbert M; Apfelbeck M; Schulz G; Gratzke C; Stief CG; Karl A
    Scand J Urol; 2017 Apr; 51(2):130-136. PubMed ID: 28332428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
    Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
    BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
    Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
    J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substaging of pT1 Urothelial Bladder Carcinoma Predicts Tumor Progression and Overall Survival.
    Grobet-Jeandin E; Wirth GJ; Benamran D; Dupont A; Tille JC; Iselin CE
    Urol Int; 2022; 106(2):130-137. PubMed ID: 33965961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.
    May M; Bastian PJ; Burger M; Bolenz C; Trojan L; Herrmann E; Wülfing C; Müller SC; Ellinger J; Buchner A; Stief CG; Tilki D; Otto W; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Wieland WF; Fritsche HM
    BJU Int; 2011 Oct; 108(8 Pt 2):E278-83. PubMed ID: 21699644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.
    Saito K; Kawakami S; Fujii Y; Sakura M; Masuda H; Kihara K
    J Urol; 2007 Dec; 178(6):2291-6; discussion 2296. PubMed ID: 17936818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Slingshot homolog-1 expression is a poor prognostic factor of pT1 bladder urothelial carcinoma after transurethral resection.
    Luo Q; Liu Y; Zhao H; Guo P; Wang Q; Li W; Li G; Wu B
    World J Urol; 2020 Nov; 38(11):2849-2856. PubMed ID: 31965287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.
    Bertz S; Denzinger S; Otto W; Wieland WF; Stoehr R; Hofstaedter F; Hartmann A
    Histopathology; 2011 Oct; 59(4):722-32. PubMed ID: 22014053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy.
    Ge P; Wang ZC; Yu X; Lin J; He Q
    BMC Urol; 2015 May; 15():46. PubMed ID: 26025446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
    Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
    Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?
    Denzinger S; Fritsche HM; Otto W; Blana A; Wieland WF; Burger M
    Eur Urol; 2008 Jan; 53(1):146-52. PubMed ID: 17624657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.